CO6160306A2 - Nueva difenilazetidiona sustituida con acido piperazina -1-sulfonico y que tiene propiedades farmacologicas mejoradas - Google Patents

Nueva difenilazetidiona sustituida con acido piperazina -1-sulfonico y que tiene propiedades farmacologicas mejoradas

Info

Publication number
CO6160306A2
CO6160306A2 CO09038965A CO09038965A CO6160306A2 CO 6160306 A2 CO6160306 A2 CO 6160306A2 CO 09038965 A CO09038965 A CO 09038965A CO 09038965 A CO09038965 A CO 09038965A CO 6160306 A2 CO6160306 A2 CO 6160306A2
Authority
CO
Colombia
Prior art keywords
inhibitors
agonists
ppar
pharmaceutical product
active ingredient
Prior art date
Application number
CO09038965A
Other languages
English (en)
Inventor
Gerhard Jaehne
Frick Wendelin
Andreas Lindenschmidt
Hubert Heuer
Hans Ludwig Schaefer
Kramer Werner
Claus Dieter Graf
Wolfgang Schmider
Original Assignee
Sanofi Aventis Deustschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deustschland Gmbh filed Critical Sanofi Aventis Deustschland Gmbh
Publication of CO6160306A2 publication Critical patent/CO6160306A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

1.- Un compuesto de fórmula Iy sus sales farmacéuticamente aceptables. 2.- Un producto farmacéutico que comprende el compuesto según la reivindicación 1. 3.- Un producto farmacéutico que comprende el compuesto según la reivindicación 1 y por lo menos un ingrediente activo adicional. 4.- El producto farmacéutico según la reivindicación 3, que comprende como ingrediente activo adicional uno o más compuestos que normalizan el metabolismo de lípidos. 5.- Un producto farmacéutico según la reivindicación 3 ó 4, que comprende, como ingrediente activo adicional, uno o más antidiabéticos, ingredientes activos hipoglucémicos, agentes antiobesidad, anorexígenos, inhibidores de HMGCoA reductasa, inhibidores de absorción del colesterol, agonistas de PPAR gamma, agonistas de PPAR alfa, agonistas de PPAR alfa/gamma, agonistas de PPAR delta, agonistas/antagonistas parciales de PPAR gamma, fibratos, inhibidores de MTP, inhibidores de CETP, inhibidores de absorción de ácidos biliares, adsorbentes de ácido biliar polimérico, inductores del receptor de LDL, inhibidores de ACAT, antioxidantes, vitaminas, moduladores de lipoproteína lipasa, inhibidores de ATP-citrato liasa, inhibidores de escualeno, sintetasa, antagonistas de lipoproteína (a), inhibidores de lipasa, insulinas, derivados de GLP-1, GLP-1, sulfonilureas, biguanidas, meglitinidas, tiazolidinadionas, inhibidores de a-glucosidasa, ingredientes activos que actúan sobre el canal de potasio dependiente de ATP de las células beta, inhibidores de glucógeno fosforilasa, antagonistas del receptor de glucagón, activadores de glucocinasa, inhibidores de gluconeogénesis, inhibidores de fructosa-1,6-bisfosfatasa, moduladores del transportador de glucosa 4, inhibidores de glutamina-fructosa-6-fosfato amidotransferasa, inhibidores de dipeptidilpeptidasa IV, inhibidores de 11-beta-hidroxisteroide deshidrogenasa 1, inhibidores de proteína tirosina fosfatasa 1B, ...
CO09038965A 2006-11-02 2009-04-17 Nueva difenilazetidiona sustituida con acido piperazina -1-sulfonico y que tiene propiedades farmacologicas mejoradas CO6160306A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102006051655 2006-11-02

Publications (1)

Publication Number Publication Date
CO6160306A2 true CO6160306A2 (es) 2010-05-20

Family

ID=38875004

Family Applications (1)

Application Number Title Priority Date Filing Date
CO09038965A CO6160306A2 (es) 2006-11-02 2009-04-17 Nueva difenilazetidiona sustituida con acido piperazina -1-sulfonico y que tiene propiedades farmacologicas mejoradas

Country Status (20)

Country Link
US (1) US20090264402A1 (es)
EP (1) EP2091915A1 (es)
JP (1) JP2010508313A (es)
KR (1) KR20090091120A (es)
CN (1) CN101535249A (es)
AR (1) AR063747A1 (es)
AU (1) AU2007315327A1 (es)
BR (1) BRPI0718052A2 (es)
CA (1) CA2668094A1 (es)
CL (1) CL2007003175A1 (es)
CO (1) CO6160306A2 (es)
IL (1) IL198427A0 (es)
MA (1) MA30819B1 (es)
MX (1) MX2009003823A (es)
NO (1) NO20091746L (es)
RU (1) RU2009120679A (es)
TW (1) TW200826941A (es)
UY (1) UY30682A1 (es)
WO (1) WO2008052658A1 (es)
ZA (1) ZA200901981B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200806623A (en) * 2005-10-05 2008-02-01 Merck & Co Inc Anti-hypercholesterolemic compounds
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US20100286112A1 (en) 2007-09-10 2010-11-11 Oscar Barba Compounds for the treatment of metabolic disorders
US9212175B2 (en) 2009-03-06 2015-12-15 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2612669A4 (en) 2010-08-31 2014-05-14 Snu R&Db Foundation USING THE FÖTAL REPROGRAMMING OF A PPAR AGONIST
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PE20160122A1 (es) 2013-03-13 2016-02-12 Forma Therapeutics Inc Compuestos nobles y composiciones para la inhibicion de fasn
CN104193731B (zh) * 2014-08-27 2017-03-15 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
CN104513187B (zh) * 2015-01-09 2017-05-31 安润医药科技（苏州）有限公司 依折麦布及其中间体的合成方法
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
CN113382633A (zh) 2018-10-29 2021-09-10 福马治疗股份有限公司 (4-(2-氟-4-(1-甲基-1H-苯并[d]咪唑-5-基)苯甲酰基)哌嗪-1-基)(1-羟基环丙基)甲酮的固体形式

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10227506A1 (de) * 2002-06-19 2004-01-08 Aventis Pharma Deutschland Gmbh Ringsubstituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
DE102005055726A1 (de) * 2005-11-23 2007-08-30 Sanofi-Aventis Deutschland Gmbh Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US20090312302A1 (en) * 2008-06-17 2009-12-17 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating nonalcoholic fatty liver disease-associated disorders

Also Published As

Publication number Publication date
KR20090091120A (ko) 2009-08-26
MX2009003823A (es) 2009-05-11
WO2008052658A1 (de) 2008-05-08
UY30682A1 (es) 2008-07-03
AR063747A1 (es) 2009-02-18
NO20091746L (no) 2009-07-21
CA2668094A1 (en) 2008-05-08
MA30819B1 (fr) 2009-10-01
TW200826941A (en) 2008-07-01
IL198427A0 (en) 2010-02-17
BRPI0718052A2 (pt) 2015-06-16
RU2009120679A (ru) 2010-12-10
ZA200901981B (en) 2010-03-31
AU2007315327A1 (en) 2008-05-08
US20090264402A1 (en) 2009-10-22
CL2007003175A1 (es) 2008-05-16
CN101535249A (zh) 2009-09-16
EP2091915A1 (de) 2009-08-26
JP2010508313A (ja) 2010-03-18

Similar Documents

Publication Publication Date Title
CO6160306A2 (es) Nueva difenilazetidiona sustituida con acido piperazina -1-sulfonico y que tiene propiedades farmacologicas mejoradas
Vultaggio-Poma et al. Extracellular ATP: a feasible target for cancer therapy
ECSP099451A (es) Compuestos de urea policíclicos antibacterianos
Kim et al. Zoledronate enhances osteocyte-mediated osteoclast differentiation by IL-6/RANKL axis
CL2007002880A1 (es) Formulacion estable que comprende un tampon de acido acetico, un tampon de acido glutamico o un tampon de acido succinico con un ph de 4,5 a 7, por lo menos un excipiente que comprende un azucar o un poliol, y un anticuerpo anti-receptor del factor d
BRPI0514731A (pt) derivados de pirimidina
PE20051140A1 (es) Compuestos de pirazolina sustituida y su preparacion como medicamentos
TN2011000245A1 (en) Organic compounds
CL2011000516A1 (es) Compuestos heterociclos espiro tetracondensados, modulares de la ctividad de la beta-secretasa; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles en el tratamiento de la enfermedad de alzheimer.
BRPI0408347B8 (pt) derivados de pirimidina, seu uso, e composição e combinação farmacêuticas
PE20120648A1 (es) Compuestos de 4-isopropilfenilglucitol como inhibidores de sglt1
ECSP10010419A (es) Derivados heterocíclicos de urea y métodos de uso de los mismos-211
AR052082A1 (es) Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante el incremento de la concentracion sanguinea de gelp -1
UY27705A1 (es) Compuestos quimicos.
Szentléleky et al. Pituitary adenylate cyclase activating polypeptide (PACAP) reduces oxidative and mechanical stress-evoked matrix degradation in chondrifying cell cultures
BR112012027545A8 (pt) Composto, composição farmacêutica, uso da composição farmacêutica e uso de um composto
US20220296594A1 (en) Potentiators of antimicrobial and/or antiviral agents
CL2007001663A1 (es) Uso de un antagonista de cgrp de formula definida (a), sus enantiomeros, sus diastereomeros, sus mezclas y sus sales para preparar un medicamento util para prevenir o tratar el dolor visceral.
MY155230A (en) Sulfoximine-substituted aniline pyrimidine derivatives as cdk inhibitors, their manufacture and use as medicine
BRPI1010300B8 (pt) processos para a preparação de um composto, de dronedarone, ou um sal do mesmo, de uma formulação farmacêutica, e de um intermediário de dronedarone, ou um sal do mesmo
Lee et al. Bacterial AmpD at the crossroads of peptidoglycan recycling and manifestation of antibiotic resistance
Brodski et al. Crosstalk of intercellular signaling pathways in the generation of midbrain dopaminergic neurons in vivo and from stem cells
ECSP10010659A (es) Derivados heterocíclicos de la urea y sus métodos de empleo
Szűcs et al. Reprogramming of the antibacterial drug vancomycin results in potent antiviral agents devoid of antibacterial activity
Madia et al. Design, synthesis and biological evaluation of new pyrimidine derivatives as anticancer agents